Wai Yuen Tong Medicine Holdings Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Ching Ho Tang
Chief executive officer
HK$23.6m
Total compensation
CEO salary percentage | 44.6% |
CEO tenure | 6.7yrs |
CEO ownership | n/a |
Management average tenure | 3.5yrs |
Board average tenure | 5.3yrs |
Recent management updates
Recent updates
Wai Yuen Tong Medicine Holdings Limited's (HKG:897) Low P/S No Reason For Excitement
Nov 19Wai Yuen Tong Medicine Holdings Limited's (HKG:897) Share Price Boosted 51% But Its Business Prospects Need A Lift Too
Jul 26Investors Give Wai Yuen Tong Medicine Holdings Limited (HKG:897) Shares A 46% Hiding
Mar 11The Strong Earnings Posted By Wai Yuen Tong Medicine Holdings (HKG:897) Are A Good Indication Of The Strength Of The Business
Dec 28Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?
Jul 11Wai Yuen Tong Medicine Holdings (HKG:897) Takes On Some Risk With Its Use Of Debt
Jul 05Is Wai Yuen Tong Medicine Holdings (HKG:897) A Risky Investment?
Mar 08Increases to Wai Yuen Tong Medicine Holdings Limited's (HKG:897) CEO Compensation Might Cool off for now
Aug 18Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?
Mar 17Wai Yuen Tong Medicine Holdings' (HKG:897) Shareholders Are Down 75% On Their Shares
Jan 22Health Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?
Dec 16CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | HK$2m |
Jun 30 2024 | n/a | n/a | -HK$12m |
Mar 31 2024 | HK$24m | HK$11m | -HK$27m |
Sep 30 2023 | n/a | n/a | HK$36m |
Jun 30 2023 | n/a | n/a | HK$8m |
Mar 31 2023 | HK$16m | HK$15m | -HK$16m |
Dec 31 2022 | n/a | n/a | -HK$98m |
Sep 30 2022 | n/a | n/a | -HK$176m |
Jun 30 2022 | n/a | n/a | -HK$143m |
Mar 31 2022 | HK$9m | HK$8m | -HK$109m |
Dec 31 2021 | n/a | n/a | -HK$122m |
Sep 30 2021 | n/a | n/a | -HK$135m |
Jun 30 2021 | n/a | n/a | -HK$255m |
Mar 31 2021 | HK$8m | HK$8m | -HK$376m |
Dec 31 2020 | n/a | n/a | -HK$98m |
Sep 30 2020 | n/a | n/a | HK$179m |
Jun 30 2020 | n/a | n/a | HK$309m |
Mar 31 2020 | HK$15m | HK$12m | HK$439m |
Dec 31 2019 | n/a | n/a | HK$253m |
Sep 30 2019 | n/a | n/a | HK$66m |
Jun 30 2019 | n/a | n/a | HK$71m |
Mar 31 2019 | HK$14m | HK$12m | HK$75m |
Dec 31 2018 | n/a | n/a | HK$20m |
Sep 30 2018 | n/a | n/a | -HK$35m |
Jun 30 2018 | n/a | n/a | -HK$75m |
Mar 31 2018 | HK$13m | HK$12m | -HK$116m |
Compensation vs Market: Ching Ho's total compensation ($USD3.03M) is above average for companies of similar size in the Hong Kong market ($USD230.70K).
Compensation vs Earnings: Ching Ho's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Ching Ho Tang (62 yo)
6.7yrs
Tenure
HK$23,551,000
Compensation
Mr. Ching Ho Tang, GBS, SBS, JP is Chairman of China Agri-Products Exchange Limited since February 8, 2021 and re-designated as its Executive Director since October 01, 2022. Mr. Tang Co-founded Wang On Gr...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman & MD | 6.7yrs | HK$23.55m | no data | |
Executive Director | 6.7yrs | HK$2.20m | no data | |
Assistant GM of Purchasing Processing & Executive Director | 3.8yrs | HK$909.00k | no data | |
Financial Controller | 2.8yrs | no data | no data | |
Head of Factory Operations | 3.3yrs | no data | no data | |
Company Secretary | less than a year | no data | no data |
3.5yrs
Average Tenure
55yo
Average Age
Experienced Management: 897's management team is considered experienced (3.5 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman & MD | 23.3yrs | HK$23.55m | no data | |
Executive Director | 6.7yrs | HK$2.20m | no data | |
Assistant GM of Purchasing Processing & Executive Director | 3.8yrs | HK$909.00k | no data | |
Independent Non-Executive Director | 9.8yrs | HK$204.00k | no data | |
Independent Non-Executive Director | less than a year | HK$45.00k | no data | |
Independent Non-Executive Director | less than a year | HK$45.00k | no data |
5.3yrs
Average Tenure
61.5yo
Average Age
Experienced Board: 897's board of directors are considered experienced (5.3 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 00:02 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Wai Yuen Tong Medicine Holdings Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|